Tag: renal denervation

TARGET BP I trial enrols its first patient

The first patient has been randomised in the TARGET BP I trial at the Piedmont Heart Institute in Atlanta, USA, to investigate the use...

EuroPCR 2019: Renal denervation linked to reduction in subclinical atrial fibrillation

Data presented at EuroPCR today indicates that renal denervation with the Symplicity system (Medtronic) is associated with a reduction in subclinical atrial fibrillation in...

RADIANCE SOLO HTN finds greater blood pressure drop after renal denervation

Six-month "on-medication" results from the RADIANCE-HTN SOLO clinical trial have found that patients treated with the Paradise ultrasound denervation system (ReCor Medical Inc.) were...

CRT 2019: Renal denervation using alcohol “seems very effective”

 The renal denervation bubble collapsed due to a single trial—SYMPLICITY HTN-3, but this trial’s findings went against the grain, Horst Sievert (Frankfurt, Germany) tells...

CRT 2019: Redesigning the resurgence of renal denervation

 David Kandzari (Atlanta, USA) tells Cardiovascular News at CRT 2019 that renal denervation is typically showing magnitudes of blood pressure reduction that are clinically...

The resurgence of renal denervation

More than ever before, arterial hypertension represents one of the greatest health threats and challenges for both patients and treating physicians. With the new...

US FDA approve new study of Medtronic’s Spyral renal denervation system

The FDA have given Medtronic approval to begin a clinical trial to evaluate the Symplicity Spyral renal denervation system in patients with hypertension who...

Otsuka Medical Devices, Otsuak Holdings, and ReCor Medical to merge

Otsuka Holdings, Otsuka Medical Devices, and ReCor Medical have signed a merger agreement pursuant to which Otsuka Holdings will acquire the remaining shares in...

FDA approves RADIANCE-II study of Paradise ultrasound denervation system

The RADIANCE-II study of the Paradise Ultrasound Denervation System (ReCor Medical) for the treatment of hypertension has been approved by the US Food &...

EuroPCR 2018: Will SPYRAL-ON change my practice?

In this PCR video, David E Kandzari (Department of Interventional Cardiology, Piedmont Heart Institute, Atlanta, USA) speaks to Atul Pathak (National Institute of Health and...

EuroPCR 2018: Positive data for renal denervation reignites interest in...

After two studies indicated that renal denervation lowers blood pressure both with and without antihypertensive drugs, Felix Mahfoud (Klinik für Innere Medizin III, Saarland...

New trial of Symplicity Spyral approved

Medtronic has announced US FDA approval to begin an investigational device exemption (IDE) pivotal trial to evaluate its Symplicity Spyral renal denervation system in...

From SYMPLICITY HTN-1 to SPYRAL HTN-OFF MED: The story of renal...

It is now almost a decade since the first patient underwent catheter-based renal denervation as a participant in a safety and proof-of concept study...

ESC 2017: MobiusHD implant shown to reduce resistant hypertension

The European results of the first-in-human trial of Vascular Dynamics’ MobiusHD implant indicate that the device is associated with a reduction in 24-hour ambulatory...

ESC 2017: SPYRAL HTN-OFF MED provides “proof of principle” that renal...

Results from SPYRAL HTN-OFF MED indicate that renal denervation, compared with a sham procedure, significantly reduces blood pressure in patients with hypertension who are...

Renal denervation devices are alternatives to drug therapy, Technavio reports

Analysts from Technavio have forecast the global renal denervation market to grow at a compound annular growth rate of close to 12% during the...